Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002315 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00002315: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002315 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002315, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
Interventions
- DRUG Acyclovir
- DRUG Netivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Phase | Phase 3 |
What the finished NCT00002315 record still lists
NCT00002315 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Acyclovir is the first listed.
NCT00002315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002315 about?
NCT00002315 is a clinical study titled "A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems". To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
What is the current status of trial NCT00002315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants.
What interventions are being tested in trial NCT00002315?
The interventions under investigation include: Acyclovir (DRUG), Netivudine (DRUG).
Who is sponsoring clinical trial NCT00002315?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002315's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository